Hengrui Medicine Investment Quality Review (600276.SH)

Quality score: 64/100 Valuation position: current price/base FV 3.25 Final signal: AVOID

Core Conclusion

Hengrui Medicine is AVOID. Current price is CNY53.60, far above conservative/base FV of CNY15.65/CNY16.48, and the 64/100 quality score fails the excellent-company gate.

Business And Quality

Five-year revenue CAGR is 5.1% and latest-year FCF is CNY8.27bn. The report treats innovation execution, pricing policy, FCF durability, and evidence constraints as insufficient to justify the current valuation.

Financial Audit

The review uses fiscal 2021-2025 in CNY. Five-year average FCF/Net Income is 0.81 and OCF/Net Income is 1.19. Latest net cash is CNY40.88bn. Market value is about CNY355.75bn on roughly 6.637bn shares.

Valuation

The valuation uses normalized FCF, a 1.7% CNY 10Y yield dated 2026-07-27, and separate balance-sheet adjustments. Price/base FV of 3.25 means the market price already assumes far more durable growth than the report is willing to underwrite.

Buy And Monitor

Current action is avoid. Reconsideration requires price/base FV below 0.70, quality score above 75, and better evidence that R&D productivity and FCF can compound without excessive risk. Track revenue trend, FCF/Net Income, ROIC, net cash/debt, dividends, buybacks, and governance disclosure.

Risks

Risks include drug pricing pressure, pipeline disappointment, R&D expense volatility, weaker FCF conversion, and governance or capital allocation issues. Any FCF/Net Income deterioration would further pressure FV.

Sources

Sources are public quote and financial data platforms, official filings or company IR, and ChinaBond for the CNY risk-free rate. Research only, not personalized investment advice.